SOURCE: diaDexus, Inc.

Diadexus, Inc.

March 10, 2015 16:00 ET

Diadexus, Inc. Highlights Upcoming Oral Presentation of Data From the PLAC® Activity Test Validation Study at the EAS Meeting

Oral Presentation on March 24, 2015 at 5:45 pm GMT

SOUTH SAN FRANCISCO, CA--(Marketwired - Mar 10, 2015) - Diadexus, Inc. (OTCQB: DDXS), a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, today announced that data validating the clinical performance of the PLAC® Test for Lp-PLA2 Activity (PLAC® Activity Test) has been accepted for oral presentation at the European Atherosclerosis Society 83rd Congress in Glasgow, UK from March 21-25, 2015. This will be the first presentation of clinical validation data evaluated by the U.S. Food and Drug Administration that led to 510(k) clearance of the PLAC Activity Test in December 2014.

About the Oral Presentation

Title: "Lipoprotein-associated phospholipase A2 (Lp-PLA2) activity and coronary heart disease risk in a biracial cohort: the REasons for Geographic And Racial Differences in Stroke (REGARDS) cohort"

Lead Author: Mary Cushman, M.D., M.Sc., Professor of Medicine and Pathology, Department of Medicine, University of Vermont

Time: March 24, 2015 at 5:45 pm Greenwich Mean Time (9:45 am Pacific Time)

For further information: http://www.eas2015.kenes.com/

About the PLAC® Test for Lp-PLA2 Activity

The PLAC® Test for Lp-PLA2 Activity, cleared by the U.S. FDA in December 2014, is to be used in conjunction with clinical evaluation and patient risk assessment as an aid in predicting risk of coronary heart disease (CHD) in patients with no prior history of cardiovascular events, which represents approximately 75% of the U.S. population. Lp-PLA2 (lipoprotein-associated phospholipase A2) is a cardiovascular risk marker supported by a decade of peer-reviewed literature. Lp-PLA2 provides important new information about blood vessel inflammation, over and above the traditional risk factors measured on a lipid panel.

For more information about the test, visit http://placactivity.com/.

About Diadexus, Inc.

Diadexus, based in South San Francisco, California, is a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, providing healthcare providers with actionable information for managing patients. The Company pioneered the testing of Lp-PLA2 (lipoprotein-associated phospholipase A2), a marker of vascular-specific inflammation that provides new information, over and above traditional risk factors measured in a lipid panel, and has over a decade of peer-reviewed literature validating this biomarker's utility. Diadexus' products are the only two FDA-cleared tests to measure Lp-PLA2: The PLAC® Test ELISA Kit first cleared by the FDA in 2003 and The PLAC® Test for Lp-PLA2 Activity cleared in December 2014.

The Company also has a pipeline of biomarkers for heart failure, proADM, proET-1 and proANP, with each providing distinct, additive information for healthcare providers over currently available markers. Diadexus also provides services to pharmaceutical partners to address the need to incorporate biomarkers in clinical development. For more information, please visit the Company's website at www.diadexus.com.

Contact Information

  • CONTACT:
    Amy Figueroa, CFA
    650-246-6424
    Investor Relations and Corporate Communications
    Email Contact